A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of DU-176b in patients with non-valvular atrial fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy

Trial Profile

A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study of DU-176b in patients with non-valvular atrial fibrillation (NVAF) aged 80 years or older who are ineligible for available oral anticoagulation therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms ELDERCARE-AF
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 25 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 15 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top